How much do superbugs cost Australian hospitals? An evidence-based open-access tool.
Infect Dis Health
; 23(1): 54-56, 2018 03.
Article
en En
| MEDLINE
| ID: mdl-30479305
ABSTRACT
Drug resistant "superbugs" are on the rise and pose a considerable threat. Little is known of their impact on health outcomes and costs to health services at a country-level. Local and relevant estimates that are realistic and derived with a transparent method can stimulate and inform policy responses. We describe an innovative online open-access tool, ResImpact that provides estimates of the national cost of common drug-resistant infections in Australia. Users are able to modify the proportion of five resistant organisms and be presented with an estimate of the associated healthcare costs. By translating complex economic data into a practical and user-friendly output, policy makers and other health professionals can improve their policy response for the Australian healthcare system.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Farmacorresistencia Microbiana
/
Costos de la Atención en Salud
/
Bacteriemia
Tipo de estudio:
Health_economic_evaluation
Límite:
Humans
País/Región como asunto:
Oceania
Idioma:
En
Revista:
Infect Dis Health
Año:
2018
Tipo del documento:
Article